Press Releases
- Active Biotech Interim Report Q3 2025
- Preclinical data of tasquinimod in combination with T cell activation to be presented at ASH 2025
- NOTICE OF EXTRAORDINARY GENERAL MEETING
- Active Biotech announces a fully secured rights issue of approximately SEK 70 million
- Positive results from Active Biotech’s clinical phase I LION study to be presented at AAO 2025 in October